Hydroxycarbamide Market Report

Hydroxycarbamide is a chemotherapy drug used in the treatment of sickle-cell disease, cervical cancer, chronic myelogenous leukemia, and polycythemia vera. It is also known as hydroxyurea and hydrea. It usually comes in the form of capsule and taken by mouth. This drug can also help the patients suffering from chronic myelomonocytic leukemia to live longer. It has the ability to bring the number of white blood cells as well as monocytes back to normal. Manufacturers are trying to enhance the efficiency and usefulness of these drugs with the help of latest technologies.

The Hydroxycarbamide market has been undergoing novel product launches. Cytodrox Capsule is one of them. It helps in preventing the cancer cells from multiplying. It increases the fetal haemoglobin (HbF) levels in RBCs in case of sickle cell diseases. This eventually enhances the blood flow and offers protection against painful sickle cell episodes.

Rise in the number of sickle-cell diseases to drive the market

Surge in the incidences of sickle-cell diseases across the globe is a key factor propelling the Hydroxycarbamide market growth. Increasing investments in research and development is opening novel avenues for the market. Improving access to healthcare facilities and growing patient pool are also expected to influence the market growth in the near future. Moreover, it has been observed that the demand for cost-effective drugs has been increasing, which may affect the overall market growth.

However, side effects associated with the consumption of such as loss of appetite, bone marrow suppression, shortness of breath, and psychiatric problems may curb the Hydroxycarbamide market growth to an extent. Additionally, if taken during pregnancy, Hydroxycarbamide can harm the baby, thus acting as a restraint in the Hydroxycarbamide market.

Players to launch new products to strengthen their presence in the market

Key manufacturers operating in the global Hydroxycarbamide market include Zydus Cadila, Taj Pharma, Qilu Pharmaceutical, Teva Pharma, United Biotech, Alkem (Cytomed), Par Pharma, Cipla, Samarth Pharma, VHB Life Sciences, Beijing Jialin Pharma, and Khandelwal Laboratories. Key players are taking up various strategic initiatives such new product launches, partnerships, and business expansions to gain a competitive advantage in the Hydroxycarbamide market.

For instance, one of the key companies, Taj Pharma has launched THAROLAX (hydroxyurea) 500mg Capsules. These capsules are used to lessen the frequency of painful crises and decrease the need for blood transfusions in adults suffering from sickle cell anemia. They are also deployed in the treatment of various cancers such as melanoma, leukemia, and ovarian cancer.

Market Segmentation

By Product Type

●   Capsule

●   Tablet

      By Application

●   Sickle Cell Disease

●   Cancer

●   Other

FDA Warnings on the Usage of Hydroxycarbamide

The global Hydroxycarbamide market has been bifurcated on the basis of product type as capsule and tablet. Hydroxycarbamide is largely available in the form of capsules owing to its increasing demand among the end users. The global Hydroxycarbamide market has been bifurcated on the basis of application as sickle cell disease, cancer, and other diseases. Hydroxycarbamide is extensively used to treat sickle cell diseases, wherein it increases haemoglobin and lowers the number of attacks. The report gives a detailed analysis of the applications segments to the readers.

By Region

According to the WHO, in the United States, sickle-cell disease affects around 72,000 people, most of whose ancestors come from Africa. Increasing incidence of sickle cell diseases in the US, mainly among African Americans is a key factor driving the demand for Hydroxycarbamide. Asia Pacific is one of the key suppliers of Hydroxycarbamide, which is, in turn, having a positive influence on the regional market growth. Middle East and Africa is also expected to witness significant growth in the years to come owing to surge in the consumption of Hydroxycarbamide.

Life sciences is a wide branch of study that is gradually becoming an integral industry to the global economics. QYR Consulting looks at the steady transformation of the life sciences industry and its impact on the subindustries such as medical care, pharmaceutical, and medical devices. Our team of esteemed analysts have put together reports to analyze the monumental changes life sciences is expected to bring in the overall healthcare industry. These reports identify the exact turning points for the industry and open up a platform for discussing its growth.

QYR Consulting brings to you a structured analysis of the technological advancements so far, vision of the players in the industry, and the strategies they are likely to use to make their mark. The reports dissect various components of the life sciences industry to scrutinize the influential factors. To help the readers make profitable business decisions, analysts have highlighted the lucrative investment areas and upcoming business opportunities.